» Articles » PMID: 19089936

Percutaneous Coronary Intervention in Anticoagulated Patients Via Radial Artery Access

Overview
Date 2008 Dec 18
PMID 19089936
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To assess safety and feasibility of using radial artery access for percutaneous coronary intervention (PCI) in patients on oral anticoagulation without interrupting therapy.

Background: The radial artery approach for PCI is intuitively attractive for patients receiving chronic oral anticoagulation with vitamin K antagonists (VKAs) but little data exist concerning feasibility or safety of this approach in this population. The main advantage of this strategy would be to avoid bridging therapy with heparin that increases risk of thrombotic and bleeding events.

Methods: In this prospective observational study, 50 consecutive patients referred for coronary angiography underwent PCI without interrupting oral anticoagulant therapy. The main outcome measures were bleeding and thrombotic complications.

Results: The indications for permanent oral anticoagulation were as follows: atrial fibrillation in 62%, mechanical prosthesis in 24%, and venous thromboembolism in 14%. Seventy-two percent were elective cases and 28% presented with acute coronary syndromes. PCI was performed with an INR range of 1.4-3.4 with mean of 2.2 +/- 0.6. Seventy-six percent of the patients were on dual antiplatelet therapy before the procedure. No thrombotic events or excess bleeding were observed at 1 month. Only one patient had a minor hemorrhage 8 days after procedure.

Conclusions: This series suggests that for patients treated with VKAs, the use of radial artery access is feasible and safe for PCI on dual antiplatelet therapy without interrupting oral anticoagulant treatment.

Citing Articles

Primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction in a patient taking dabigatran for chronic anticoagulation.

Ahmed I, Voyce S Tex Heart Inst J. 2015; 42(2):158-61.

PMID: 25873830 PMC: 4382885. DOI: 10.14503/THIJ-13-3727.


Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting: hovering among bleeding risk, thromboembolic events, and stent thrombosis.

Menozzi M, Rubboli A, Manari A, De Palma R, Grilli R Thromb J. 2012; 10(1):22.

PMID: 23075316 PMC: 3502192. DOI: 10.1186/1477-9560-10-22.


The risk of bleeding of triple therapy with vitamin K-antagonists, aspirin and clopidogrel after coronary stent implantation: Facts and questions.

Rubboli A J Geriatr Cardiol. 2012; 8(4):207-14.

PMID: 22783307 PMC: 3390087. DOI: 10.3724/SP.J.1263.2011.00207.


Adequate antiplatelet regimen in patients on chronic anti-vitamin K treatment undergoing percutaneous coronary intervention.

Brugaletta S, Martin-Yuste V, Ferreira-Gonzalez I, Cola C, Alvarez-Contreras L, De Antonio M World J Cardiol. 2011; 3(11):367-73.

PMID: 22125672 PMC: 3224870. DOI: 10.4330/wjc.v3.i11.367.


Treatment of cardiovascular diseases in cancer patients.

Noutsias M, Maisch B Herz. 2011; 36(4):340-5.

PMID: 21584714 DOI: 10.1007/s00059-011-3452-5.